Discovery Services
Lowering attrition rates for new chemical entities entering expensive development phases is critical to cutting the overall costs of drug development and improve R&D productivity. With this in mind, the ability to "pick the best", and to identify potential failures sooner, are key objectives for both biotech and pharmaceutical companies.
Lowering attrition rates for new chemical entities entering expensive development phases is critical to cutting the overall costs of drug development and improve R&D productivity. With this in mind, the ability to "pick the best", and to identify potential failures sooner, are key objectives for both biotech and pharmaceutical companies.© Accelera | Credits | Terms of use